ImmunityBio, Inc. (IBRX) Posts Strong Preliminary Q1 Sales on ANKTIVA Momentum

TheFly reported connected April 9 that IBRX reported preliminary first-quarter 2026 nett merchandise gross of astir $44.2 million, exceeding the statement estimation of $43.17 million. Its pb therapy, ANKTIVA, has secured approvals oregon authorizations crossed 5 regulatory regions, covering astir 34 countries.

The institution besides confirmed that enrollment for its cardinal BCG-naive CIS survey has been completed, with the monitoring committee determining that nary further participants are needed. A supplemental biologics licence exertion remains planned for submission successful 2026. As of March 31, 2026, ImmunityBio, Inc. (NASDAQ:IBRX) held astir $380.9 cardinal successful cash, currency equivalents, and marketable securities. The institution continues to absorption connected expanding its beingness successful the U.S. portion expanding its scope crossed planetary markets.

In a abstracted move, connected April 6, IBRX responded to a connection from the FDA’s Office of Prescription Drug Promotion concerning issues identified connected March 13 related to a podcast and a tv advertisement. The institution clarified that the advertisement referenced had ne'er been broadcast and confirmed that the podcast contented successful question has been removed, with steps taken to destruct it from outer platforms. It besides outlined corrective measures, including stricter interior reappraisal processes, enhanced compliance protocols, and further oversight to guarantee aboriginal promotional materials conscionable regulatory standards.

ImmunityBio, Inc. (NASDAQ:IBRX) is simply a clinical-stage biotechnology institution processing immunotherapies to dainty crab and infectious diseases. Its level focuses connected activating the immune strategy utilizing caller compartment and vaccine-based approaches to amended semipermanent diligent outcomes.

While we admit the imaginable of IBRX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years 

Disclosure: None. Follow Insider Monkey connected Google News.